Adipose tissue retains a ‘memory’ of obesity through cellular transcriptional and epigenetic changes that persist after weight loss, which may increase the likelihood of regaining weight, experiments in human and mouse cells show. The findings, published in Nature, could help explain the problematic ‘yo-yo effect’, the rapid weight rebound often seen with dieting.
A study conducted in several Spanish provinces has analysed the relationship between breast cancer and obesity in more than 2,000 postmenopausal women. Its findings are that around 40% of estrogen receptor positive (ER+) cases - the most common type - can be attributed to excess body fat (above 40%). This is much higher than the 10% considered attributable when only a high body mass index is taken into account. The results are published in the Journal of Epidemiology and Community Health.
A study published today in Science Advances suggests that there may be a correlation between having a high body mass index (BMI) in childhood and developing schizophrenia later in life. However, the study also indicates that having a higher BMI in adulthood may be correlated with a lower risk of schizophrenia and obsessive-compulsive disorder.
A new study presented at the annual meeting of the European Association for the Study of Diabetes (EASD), being held in Madrid from September 9-13, and published simultaneously in the New England Journal of Medicine (NEJM), has revealed that liraglutide, an anti-obesity drug, is safe and effective in children aged 6-12 years.
The use of GLP-1 analog diabetes drugs-such as semaglutide, sold under the trade name Ozempic-is not linked to an increased risk of suicide, according to two studies published in JAMA Internal Medicine. The first, led by a U.S. team, analyzes data from more than 3,300 people who have participated in clinical trials. The second analyzes data from 124,517 users of these drugs in Sweden and Denmark, and compares them with an even larger group of people who used another type of diabetes medication.
In research using a WHO database of adverse drug reactions, the authors identified a signal of disproportionality of suicidal ideation with semaglutide, one of the drugs used to treat type 2 diabetes and obesity. The study, published in JAMA Network Open, did not find this signal for liraglutide, another drug indicated for these treatments.
A paper published today in the journal Science explores the potential of glucagon-like peptide-1 (GLP-1)-based drugs such as semaglutide to treat diseases beyond diabetes and obesity. For example, recent studies suggest that they could improve conditions ranging from depression to neurological disorders to cardiovascular and kidney disease.
The use of the antidepressants escitalopram, paroxetine, and duloxetine is associated with greater weight gain than the use of sertraline, according to the results of an analysis comparing data from more than 183,000 adults treated with one of eight types of antidepressants. Among these, bupropion is associated with the least weight gain, concludes the study, which is published in Annals of Internal Medicine.
About one in 5,000 people have a genetic variant in the SMIM1 gene that results in a particular type of blood type called Vel negative. An international team of researchers now describes the same variant as being associated with a predisposition to obesity, metabolic disturbances and lower resting energy expenditure. Women studied with the variant weigh, on average, 4.6 kg more, while in men the difference is about 2.4 kg. The results are published in the journal Med, published by the Cell group.
The Spanish Agency of Medicines and Health Products (AEMPS) has announced that the anti-obesity drug Wegovy (semaglutide) will be available, with a doctor’s prescription, starting from May. It is the same active ingredient as Ozempic, but for patients without diabetes.